CN1954845B - 一种肿节风复方药物组合物及其制备方法 - Google Patents
一种肿节风复方药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1954845B CN1954845B CN200510104372XA CN200510104372A CN1954845B CN 1954845 B CN1954845 B CN 1954845B CN 200510104372X A CN200510104372X A CN 200510104372XA CN 200510104372 A CN200510104372 A CN 200510104372A CN 1954845 B CN1954845 B CN 1954845B
- Authority
- CN
- China
- Prior art keywords
- extract
- caulis marsdeniae
- injection
- marsdeniae tenacissimae
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 59
- 241000736026 Sarcandra Species 0.000 title claims description 24
- 239000002131 composite material Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 title description 7
- 239000000284 extract Substances 0.000 claims abstract description 232
- 239000003814 drug Substances 0.000 claims abstract description 101
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 28
- 239000007924 injection Substances 0.000 claims description 108
- 238000002347 injection Methods 0.000 claims description 108
- 239000010263 Marsdeniae tenacissimae extract Substances 0.000 claims description 94
- 229940079593 drug Drugs 0.000 claims description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000000890 drug combination Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 13
- 150000007965 phenolic acids Chemical class 0.000 claims description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 9
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 9
- 229930182470 glycoside Natural products 0.000 claims description 9
- 150000002338 glycosides Chemical class 0.000 claims description 9
- 235000009048 phenolic acids Nutrition 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000001671 coumarin Nutrition 0.000 claims description 7
- 150000004775 coumarins Chemical class 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 2
- 240000004274 Sarcandra glabra Species 0.000 abstract description 2
- 229940090044 injection Drugs 0.000 description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 67
- 238000012360 testing method Methods 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 57
- 230000002401 inhibitory effect Effects 0.000 description 41
- 229960004756 ethanol Drugs 0.000 description 37
- 230000000694 effects Effects 0.000 description 33
- 238000003756 stirring Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 21
- 239000008215 water for injection Substances 0.000 description 21
- 229960004397 cyclophosphamide Drugs 0.000 description 20
- 239000000796 flavoring agent Substances 0.000 description 18
- 235000019634 flavors Nutrition 0.000 description 18
- 239000008187 granular material Substances 0.000 description 18
- 239000010297 uvangoletin Substances 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 17
- 239000012567 medical material Substances 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 16
- 229920000053 polysorbate 80 Polymers 0.000 description 16
- 239000013558 reference substance Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 239000008354 sodium chloride injection Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 201000007270 liver cancer Diseases 0.000 description 14
- 208000014018 liver neoplasm Diseases 0.000 description 14
- 238000004064 recycling Methods 0.000 description 14
- 230000001476 alcoholic effect Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 238000012856 packing Methods 0.000 description 11
- 238000001959 radiotherapy Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000001694 spray drying Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000011265 semifinished product Substances 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229940023488 pill Drugs 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000008227 sterile water for injection Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- -1 sheet Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000758719 Chloranthaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241001125690 Marsdenia tenacissima Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 235000010842 Sarcandra glabra Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- GLMWWMZIEZJGMT-UHFFFAOYSA-N chloroform;formic acid;propan-2-one Chemical compound OC=O.CC(C)=O.ClC(Cl)Cl GLMWWMZIEZJGMT-UHFFFAOYSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- BLKQDSMHWQPNJU-UHFFFAOYSA-N n-(cyanomethyl)-n-(furan-2-ylmethyl)-3,4-dimethoxybenzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N(CC#N)CC1=CC=CO1 BLKQDSMHWQPNJU-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510104372XA CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510104372XA CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1954845A CN1954845A (zh) | 2007-05-02 |
CN1954845B true CN1954845B (zh) | 2012-03-07 |
Family
ID=38062517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510104372XA Expired - Fee Related CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1954845B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412261A (zh) * | 2015-11-27 | 2016-03-23 | 深圳福山生物科技有限公司 | 一种药物组合物的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1372971A (zh) * | 2002-03-21 | 2002-10-09 | 张平 | 一种治疗癌症的中药注射液 |
CN1410110A (zh) * | 2002-11-19 | 2003-04-16 | 大连金港制药有限公司 | 含肿节风中药制剂作为制备治疗抗癌药物副作用药的应用 |
-
2005
- 2005-10-27 CN CN200510104372XA patent/CN1954845B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1372971A (zh) * | 2002-03-21 | 2002-10-09 | 张平 | 一种治疗癌症的中药注射液 |
CN1410110A (zh) * | 2002-11-19 | 2003-04-16 | 大连金港制药有限公司 | 含肿节风中药制剂作为制备治疗抗癌药物副作用药的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1954845A (zh) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN102657823B (zh) | 一种具有抗癌作用的中药组合物及其制备方法和检测方法 | |
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN1981857A (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN1977885B (zh) | 一种抗肝炎药物组合物 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN1985873B (zh) | 甘草酸或其盐、人参和黄芪的药物组合物 | |
CN1954838B (zh) | 一种抗肿瘤的药物组合物 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN1954845B (zh) | 一种肿节风复方药物组合物及其制备方法 | |
CN1954839B (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
CN1961894B (zh) | 一种新的复方药物组合物及其制备方法和用途 | |
CN1939417B (zh) | 北豆根与金果榄或其提取物的药物组合物 | |
CN101073611B (zh) | 一种抗肿瘤的药物组合物 | |
CN1970001B (zh) | 一种苦参素、五味子和人参配伍的治疗肝炎的药物组合物 | |
CN101073564B (zh) | 一种含l-谷氨酰胺的药物组合物 | |
CN1961908B (zh) | 一种抗肿瘤药物组合物及其制备方法 | |
CN1977888B (zh) | 一种由黄芩苷、灵芝和丹参制成的药物组合物 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN100584349C (zh) | 一种中西复方药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120307 Termination date: 20181027 |
|
CF01 | Termination of patent right due to non-payment of annual fee |